Tillkännagivande • May 10
Biolife Solutions, Inc. Reiterates Earnings Guidance for 2026 BioLife Solutions, Inc. reiterated earnings guidance for 2026. For the year, the company expected revenue of $112.5 million to $115.0 million, representing growth of 17% to 20% compared with 2025 revenue from continuing operations; Net income (GAAP) for the full year. Tillkännagivande • Apr 24
BioLife Solutions, Inc. to Report Q1, 2026 Results on May 07, 2026 BioLife Solutions, Inc. announced that they will report Q1, 2026 results on May 07, 2026 Tillkännagivande • Feb 27
BioLife Solutions, Inc. Provides Earnings Guidance for 2026 BioLife Solutions, Inc. provided earnings guidance for 2026. For the year, the company expected revenue of $112.5 million to $115.0 million, representing growth of 17% to 20% compared with 2025 revenue from continuing operations; Net income (GAAP) for the full year. Tillkännagivande • Feb 17
BioLife Solutions, Inc. to Report Q4, 2025 Results on Feb 26, 2026 BioLife Solutions, Inc. announced that they will report Q4, 2025 results on Feb 26, 2026 Tillkännagivande • Jan 12
BioLife Solutions, Inc. Announces Retirement of Karen Foster as Chief Quality and Operations Officer, Effective March 31, 2026 On January 8, 2026, BioLife Solutions, Inc. announced that Karen Foster, the Chief Quality and Operations Officer, provided notice of her decision to retire from her position as Chief Quality and Operations Officer of the Company, effective March 31, 2026. Tillkännagivande • Nov 08
BioLife Solutions, Inc. Updates Earnings Guidance for the Fiscal Year 2025 BioLife Solutions, Inc. updated earnings guidance for the fiscal year 2025. Following the sale of its evo cold chain logistics business in early October, BioLife Solutions is updating its 2025 revenue guidance. Total 2025 revenue guidance, adjusted for the sale of evo, is $95.0 million to $96.0 million, representing an increase of 27% - 29% when compared to 2024 continuing operations revenues on a like for like basis. This guidance is based on the following expectations: Cell Processing platform revenue: Raised to $93.0 million to $94.0 million from prior guidance of $91.0 million to $93.0 million, representing year-over-year growth of 26% to 28%. Tillkännagivande • Oct 24
BioLife Solutions, Inc. to Report Q3, 2025 Results on Nov 06, 2025 BioLife Solutions, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Tillkännagivande • Oct 08
Peli BioThermal LLC acquired SAVSU Cleo Technologies, LLC from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $25.5 million. Peli BioThermal LLC acquired SAVSU Cleo Technologies, LLC from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $25.5 million on October 7, 2025. The cash purchase price of $25.5 million is subject to certain adjustments. David Zimbalist and Molly Kathleen of EC M&A acted as financial advisor to BioLife Solutions, Inc. Gibson Dunn & Crutcher LLP served as legal counsel to Peli BioThermal LLC and Platinum Equity, LLC.
Peli BioThermal LLC completed the acquisition of SAVSU Cleo Technologies, LLC from BioLife Solutions, Inc. (NasdaqCM:BLFS) on October 7, 2025. Tillkännagivande • Aug 08
BioLife Solutions, Inc. Revises Earnings Guidance for the Year 2025 BioLife Solutions, Inc. revised earnings guidance for the year 2025. For the period, company now expects revenue guidance to $100.0 million to $103.0 million from prior guidance of $95.5 million to $99.0 million, representing growth of 22% to 25% compared with 2024. This guidance is based on the following expectations: Cell Processing platform revenue: Revised to $91.0 million to $93.0 million from prior guidance of $86.5 million to $89.0 million. The revised guidance reflects a year-over-year growth of 24% to 26%. evo and Thaw platform revenue: Affirms guidance of $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%. Tillkännagivande • Jul 25
BioLife Solutions, Inc. to Report Q2, 2025 Results on Aug 07, 2025 BioLife Solutions, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Tillkännagivande • Jul 09
BioLife Solutions, Inc., Annual General Meeting, Aug 20, 2025 BioLife Solutions, Inc., Annual General Meeting, Aug 20, 2025. Tillkännagivande • May 09
Biolife Solutions, Inc. Affirms Earnings Guidance for the Year 2025 BioLife Solutions, Inc. affirmed earnings guidance for the year 2025. For the period, company expects revenue of $95.5 million to $99.0 million, representing growth of 16% to 20% compared with 2024. This is based on expectations for Cell Processing platform and evo and Thaw platform, as follows: Cell Processing platform: $86.5 million to $89.0 million, reflecting year-over-year growth of 18% to 21%. evo and Thaw platform: $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%. Management expects reduction in net loss (GAAP). Tillkännagivande • Apr 30
BioLife Solutions, Inc. to Report Q1, 2025 Results on May 08, 2025 BioLife Solutions, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Tillkännagivande • Apr 07
BioLife Solutions, Inc. (NasdaqCM:BLFS) acquired 90% stake in PanTHERA CryoSolutions Inc for $21.53 million. BioLife Solutions, Inc. (NasdaqCM:BLFS) acquired 90% stake in PanTHERA CryoSolutions Inc. for $21.53 million on April 7, 2025. A cash consideration of $9.3 million will be paid by BioLife Solutions, Inc. The consideration consists of 0.24 million common equity of BioLife Solutions, Inc. to be issued for common equity of PanTHERA CryoSolutions Inc. BioLife Solutions, Inc. will pay an earnout/contingent payment of $7.2 million cash. As part of consideration, $16.5 million is paid towards common equity of PanTHERA CryoSolutions Inc.
BioLife Solutions, Inc. (NasdaqCM:BLFS) completed the acquisition of 90% stake in PanTHERA CryoSolutions Inc. on April 7, 2025. Tillkännagivande • Mar 18
Biolife Solutions, Inc. Announces Board Changes BioLife Solutions, Inc. announced the appointment of Cathy Coste to its board of directors. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. Ms. Coste retired from Deloitte in 2020, where she most recently was a senior partner and life sciences industry executive leader. With Deloitte for more than 30 years, she served in corporate and professional services positions, ultimately leading global finance, internal audit and operations teams while participating in more than 200 audit committee meetings. Previously she worked at Mervyn's, including responsibility in accounting, FP&A and operations. Ms. Coste is a director of Biomerica, Inc., Minerva Surgical, Inc. (a public company that went private in 2024) and Renalytix plc, serving as audit committee chair for each. She holds a B.A. in business administration-accounting from California State University, Hayward, and completed Harvard Business School's Corporate Director's Certificate Program. She is a licensed Certified Public Accountant. Tillkännagivande • Mar 03
BioLife Solutions, Inc. Provides Earnings Guidance for the Year 2025 BioLife Solutions, Inc. provided earnings guidance for the year 2025. For the period, company expects revenue of $95.5 million to $99.0 million, representing growth of 16% to 20% compared with 2024. This is based on expectations for Cell Processing platform and evo and Thaw platform, as follows: Cell Processing platform: $86.5 million to $89.0 million, reflecting year-over-year growth of 18% to 21%. evo and Thaw platform: $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%. Management expects reduction in net loss (GAAP). Tillkännagivande • Feb 21
BioLife Solutions, Inc. to Report Q4, 2024 Results on Mar 03, 2025 BioLife Solutions, Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 03, 2025 Tillkännagivande • Dec 16
Biolife Solutions Inc. Appoints Tony J. Hunt to Its Board of Directors, Effective from January 2, 2025 BioLife Solutions, Inc. announced the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. Prior to being named Executive Chairman of Repligen in September 2024, Mr. Hunt served as CEO and director for nine years, having joined the firm in 2014 as Chief Operating Officer. Earlier, he was President of Bioproduction at Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008 as General Manager of Bioproduction Chromatography and Pharma Analytics. From 2000 to 2008, Mr. Hunt was Senior Director of Pharma Programs at Applied Biosystems, where he launched the Pharma Analytics business that became part of the Bioproduction platform at Life Technologies.He holds a bachelor's degree with honors in microbiology and a master's degree in biotechnology from the University of Galway, and an MBA from the Questrom School of Business at Boston University. Mr. Hunt serves on the board of directors of 908 Devices Inc., a publicly traded innovator of handheld and desktop devices for chemical analysis. Tillkännagivande • Nov 15
Standex International Corporation (NYSE:SXI) acquired Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $6.2 million. Standex International Corporation (NYSE:SXI) acquired Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $6.2 million on November 14, 2024. The transaction is being financed from Standex's existing cash balance. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex's Scientific business segment. In calendar year 2024, Custom Biogenic Systems estimates revenues of approximately $15 million.
Standex International Corporation (NYSE:SXI) completed the acquisition of Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) on November 14, 2024. Reported Earnings • Nov 13
Third quarter 2024 earnings released: US$0.037 loss per share (vs US$0.67 loss in 3Q 2023) Third quarter 2024 results: US$0.037 loss per share (improved from US$0.67 loss in 3Q 2023). Revenue: US$30.6m (down 8.3% from 3Q 2023). Net loss: US$1.70m (loss narrowed 94% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 19% per year. Tillkännagivande • Nov 13
BioLife Solutions, Inc. Revises Earnings Guidance for the Year 2024 BioLife Solutions announced that the company is revising its 2024 earnings guidance to $98.0 million to $100.0 million from prior guidance of $99.0 million to $101.0 million primarily to reflect the revenue impact of the divestiture of SciSafe on November 12, 2024. This guidance also reflects updated expectations for BioLife's Cell Processing product line and Biostorage and Services, which includes results from its ThawSTAR product line and does not include revenue from the freezer product line (GCI and CBS) or SciSafe after November 12, 2024. Tillkännagivande • Nov 12
An undisclosed buyer acquired SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS). An undisclosed buyer acquired SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for US $73 million on November 12, 2024. A cash consideration of $73 million will be paid by the buyer. In conjunction with this transaction, Todd Berard, BioLife's Chief Marketing Officer, will assume all sales and marketing functions for the Company in the newly created position of Chief Commercial Officer. Garrie Richardson, previously BioLife's Chief Revenue Officer for the last year, will join a now independent SciSafe as Chief Executive Officer. Stephens Inc. acted as financial advisor for BioLife Solutions, Inc. K&L Gates LLP acted as legal advisor for BioLife Solutions, Inc.
An undisclosed buyer completed the acquisition of SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) on November 12, 2024. Tillkännagivande • Nov 01
BioLife Solutions, Inc. to Report Q3, 2024 Results on Nov 12, 2024 BioLife Solutions, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 New Risk • Aug 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$64m Forecast net loss in 2 years: US$8.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$8.2m net loss in 2 years). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Breakeven Date Change • Aug 12
No longer forecast to breakeven The 9 analysts covering BioLife Solutions no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.39m in 2026. New consensus forecast suggests the company will make a loss of US$18.3m in 2026. Reported Earnings • Aug 09
Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.23 loss in 2Q 2023) Second quarter 2024 results: US$0.15 loss per share (improved from US$0.23 loss in 2Q 2023). Revenue: US$28.3m (down 28% from 2Q 2023). Net loss: US$7.15m (loss narrowed 30% from 2Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Tillkännagivande • Aug 09
BioLife Solutions, Inc. Updates Revenue Guidance for the Year 2024 BioLife Solutions, Inc. updated revenue guidance for the year 2024. For the year, the company expects revenue to be $99.0 million to $101.0 million from prior guidance of $95.5 million to $100.0 million. This guidance is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR® product line and do not include revenue from the freezer product line (GCI and CBS). Buy Or Sell Opportunity • Jul 31
Now 20% undervalued Over the last 90 days, the stock has risen 32% to €21.80. The fair value is estimated to be €27.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has declined by 49%. Revenue is forecast to decline by 7.3% in 2 years. Earnings are forecast to grow by 84% in the next 2 years. Tillkännagivande • Jul 26
BioLife Solutions, Inc. to Report Q2, 2024 Results on Aug 08, 2024 BioLife Solutions, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 Tillkännagivande • Jun 08
BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024 BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024. Buy Or Sell Opportunity • Jun 03
Now 20% undervalued Over the last 90 days, the stock has risen 19% to €19.60. The fair value is estimated to be €24.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has declined by 49%. Revenue is forecast to decline by 5.3% in 2 years. Earnings are forecast to grow by 84% in the next 2 years. Tillkännagivande • May 30
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions, Inc. announced the introduction of the CryoCase, an addition to its CellSeal product line. Expected to be released to CGT developers in August, the CryoCase is available for demonstration at this week's ISCT event in Vancouver, Canada. Early product evaluators stated that the CryoCase's volume versatility, rigid and protective structure, and fill and retrieval port designs, allows for easy integration with their current systems generating improved throughput and streamlined procedures. The CryoCase is the first ever cryo-compatible rigid container designed for closed-system fill and retrieval for larger volumes of fluid (<75mL). The container is transparent, enabling improved end user compliance with USP 790, USP 1790, and other international visible inspection methods, and manufactured under strict environmental and processing controls designed to limit common sources of particulates in single-use disposable manufacturing. Early user testing has shown comparable cell viability and recovery for multiple cell types compared to storage in existing bags and drop testing in a frozen state demonstrates high resistance to leaks or fractures. Initial testing indicates that the CryoCase may materially reduce or eliminate particulates inherent in cryopreservation bags. CryoCase samples are now available for testing. Breakeven Date Change • May 15
No longer forecast to breakeven The 7 analysts covering BioLife Solutions no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$63.0m in 2026. New consensus forecast suggests the company will make a loss of US$7.00m in 2026. Reported Earnings • May 10
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 1Q 2023) First quarter 2024 results: US$0.23 loss per share (improved from US$0.32 loss in 1Q 2023). Revenue: US$31.7m (down 16% from 1Q 2023). Net loss: US$10.2m (loss narrowed 26% from 1Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Tillkännagivande • May 01
BioLife Solutions, Inc. to Report Q1, 2024 Results on May 09, 2024 BioLife Solutions, Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Tillkännagivande • Apr 20
An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $2.6 million. An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $2.6 million on April 17, 2024. aggregate purchase price of $1 and transaction required $7 million in cash to remain on the balance sheet of GCI and the repayment of $2.6 million in GCI long-term debt. In connection with the BioLife Solutions, Inc.’s entry into the Purchase Agreement, the BioLife Solutions, Inc. implemented a reduction in force related to the business of Global Cooling, which will reduce the BioLife Solutions, Inc.’s workforce by approximately 47 employees (representing approximately 11% of its full-time employees). The BioLife Solutions, Inc.’s Board of Directors approved the reduction in force on March 29, 2024, and all affected employees were informed on April 17, 2024, following the execution of the Purchase Agreement.
An undisclosed buyer completed the acquisition of Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) on April 18, 2024. Recent Insider Transactions • Mar 14
Lead Director recently sold €173k worth of stock On the 13th of March, Amy DuRoss sold around 11k shares on-market at roughly €15.46 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €236k more than they bought in the last 12 months. Reported Earnings • Mar 01
Full year 2023 earnings released: US$1.52 loss per share (vs US$3.29 loss in FY 2022) Full year 2023 results: US$1.52 loss per share (improved from US$3.29 loss in FY 2022). Revenue: US$143.3m (down 11% from FY 2022). Net loss: US$66.4m (loss narrowed 53% from FY 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Breakeven Date Change • Mar 01
Forecast breakeven date pushed back to 2026 The 8 analysts covering BioLife Solutions previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 68% per year to 2025. The company is expected to make a profit of US$21.6m in 2026. Average annual earnings growth of 67% is required to achieve expected profit on schedule. Tillkännagivande • Feb 21
BioLife Solutions, Inc. to Report Q4, 2023 Results on Feb 29, 2024 BioLife Solutions, Inc. announced that they will report Q4, 2023 results on Feb 29, 2024 Reported Earnings • Nov 10
Third quarter 2023 earnings released: US$0.67 loss per share (vs US$0.23 loss in 3Q 2022) Third quarter 2023 results: US$0.67 loss per share (further deteriorated from US$0.23 loss in 3Q 2022). Revenue: US$33.3m (down 18% from 3Q 2022). Net loss: US$29.1m (loss widened 193% from 3Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Tillkännagivande • Nov 03
BioLife Solutions, Inc. to Report Q3, 2023 Results on Nov 09, 2023 BioLife Solutions, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023 Tillkännagivande • Aug 11
Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023 BioLife Solutions, Inc. provided earnings guidance for the year 2023. Total revenue for 2023 is expected to range from $144 million to $158 million, reflecting a year-over-year decrease of 11% to 2%. Excluding COVID-19-related revenue, this range reflects a year-over-year decrease of 3% to an increase of 6%. Reported Earnings • Aug 11
Second quarter 2023 earnings released: US$0.23 loss per share (vs US$1.72 loss in 2Q 2022) Second quarter 2023 results: US$0.23 loss per share (improved from US$1.72 loss in 2Q 2022). Revenue: US$39.5m (down 2.5% from 2Q 2022). Net loss: US$10.2m (loss narrowed 86% from 2Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Tillkännagivande • Jul 29
BioLife Solutions, Inc. to Report Q2, 2023 Results on Aug 08, 2023 BioLife Solutions, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023 Tillkännagivande • May 12
BioLife Solutions, Inc. announced delayed 10-Q filing On 05/11/2023, BioLife Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Reported Earnings • May 11
First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.17 loss in 1Q 2022) First quarter 2023 results: US$0.32 loss per share (further deteriorated from US$0.17 loss in 1Q 2022). Revenue: US$37.7m (up 4.1% from 1Q 2022). Net loss: US$13.7m (loss widened 94% from 1Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance. Tillkännagivande • May 11
Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023 BioLife Solutions, Inc. reaffirmed earnings guidance for the fiscal 2023. For the period, the company expects revenue to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Recent Insider Transactions • Apr 11
Chairman & CEO recently sold €59k worth of stock On the 6th of April, Michael Rice sold around 3k shares on-market at roughly €18.34 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €91k. Michael has been a net seller over the last 12 months, reducing personal holdings by €289k. Reported Earnings • Mar 18
Full year 2022 earnings released: US$3.29 loss per share (vs US$0.20 loss in FY 2021) Full year 2022 results: US$3.29 loss per share (further deteriorated from US$0.20 loss in FY 2021). Revenue: US$161.8m (up 36% from FY 2021). Net loss: US$139.8m (loss widened US$132.2m from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 142 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Mar 05
Chairman & CEO recently sold €91k worth of stock On the 1st of March, Michael Rice sold around 4k shares on-market at roughly €21.32 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Michael has been a net seller over the last 12 months, reducing personal holdings by €216k. Recent Insider Transactions • Jan 26
Director recently sold €82k worth of stock On the 19th of January, Roderick de Greef sold around 4k shares on-market at roughly €21.49 per share. This transaction amounted to 8.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €911k. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months. Recent Insider Transactions • Jan 22
Director recently sold €82k worth of stock On the 19th of January, Roderick de Greef sold around 4k shares on-market at roughly €21.49 per share. This transaction amounted to 8.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €911k. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months. Recent Insider Transactions • Nov 16
President & COO recently sold €462k worth of stock On the 14th of November, Roderick de Greef sold around 20k shares on-market at roughly €23.08 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Roderick has been a net seller over the last 12 months, reducing personal holdings by €1.4m. Reported Earnings • Nov 11
Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.002 profit in 3Q 2021) Third quarter 2022 results: US$0.23 loss per share (down from US$0.002 profit in 3Q 2021). Revenue: US$40.7m (up 21% from 3Q 2021). Net loss: US$9.96m (down US$10.0m from profit in 3Q 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Tillkännagivande • Nov 10
BioLife Solutions, Inc. Updates Revenue Guidance of 2022 BioLife Solutions, Inc. is updating revenue guidance of 2022. For the period, the company announced that total revenue is now expected to range from $160 million to $164 million compared with prior guidance of $160 million to $166 million, and reflects year-over-year growth of 34% to 38%. Tillkännagivande • Nov 03
BioLife Solutions, Inc. to Report Q3, 2022 Results on Nov 09, 2022 BioLife Solutions, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 09, 2022 Recent Insider Transactions • Oct 12
President & COO recently sold €198k worth of stock On the 7th of October, Roderick de Greef sold around 9k shares on-market at roughly €23.21 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Roderick has been a net seller over the last 12 months, reducing personal holdings by €1.0m. Tillkännagivande • Oct 04
BioLife Solutions, Inc. Announces Executive Changes BioLife Solutions, Inc. announced changes to its Board of Directors and executive management team, all to be effective as of January 3, 2023. Roderick de Greef, BioLife President and Chief Operating Officer, will retire from management and will re-join the Board of Directors, increasing the number of Directors to seven. de Greef has served BioLife for 22 years as a board member then and as an executive officer since 2016. de Greef served as Chief Financial Officer from 2016 to 2021 and postponed his previously announced retirement of December 2021 to assume the role of COO, with a focus on completing key operational improvement initiatives related to the Company's acquisition of Global Cooling, Inc. (Stirling UltraCold). Phillips joined BioLife as Vice President, ULT Freezer Product Line upon the closing of the acquisition of Global Cooling, where he held the position of Chief Operating Officer. Since joining BioLife, Phillips was promoted to Vice President of Freezer Operations with responsibility for overseeing the Company's liquid nitrogen storage freezer product lines. His career spans more than 20 years of operational executive leadership positions that include Brooks Automation (now Azenta Life Sciences) and PerkinElmer, where he held global responsibilities for a number of divisions. Phillips has a Bachelor of Science in Physics from Cardiff University and an MBA from the University of South Wales. Tillkännagivande • Aug 27
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors BioLife Solutions, Inc. announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six and as a member of the Company’s Compensation Committee and the Nominating and Governance Committee. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations. Mr. Moore has served as a member of the board of directors of Cerus Corporation (Nasdaq: CERS) since September 2018. Since April 2020, Mr. Moore has served as the President and Chief Operating Officer at PACT Pharma, Inc., or PACT, a company dedicated to engineering transformational T cell therapies. Mr. Moore served as the President and Chief Technology Officer at PACT from October 2019 to April 2020. Prior to PACT, Mr. Moore served as Executive Vice President, Technical Operations of Kite Pharma, or Kite, a company owned by Gilead Sciences, Inc. since March 2016. Prior to Kite, he spent more than 12 years at Genentech, a Roche Company, most recently as Senior Vice President, Head of Global Technical Operations – Biologics and a member of the Genentech Executive Committee. While at Genentech, he oversaw global leadership for more than 7,500 professionals across 10 internal sites and managed more than 30 contract manufacturing organizations, including end to end quality supply performance of more than 20 biological products. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). Mr. Moore is currently a member of the International Society for Pharmaceutical Engineering, PDA and has been a part of the Executive Committee of BioPhorum Operations Group. Mr. Moore is a former member of the board of directors FosunKite, a joint venture between Gilead Sciences, Inc. and Fosun Pharmaceuticals Inc. He holds a Bachelor of Science, Chemical Engineering from Tulsa University and an M.S. from Northwestern University. Reported Earnings • Aug 11
Second quarter 2022 earnings released: US$1.71 loss per share (vs US$0.20 profit in 2Q 2021) Second quarter 2022 results: US$1.71 loss per share (down from US$0.20 profit in 2Q 2021). Revenue: US$40.5m (up 30% from 2Q 2021). Net loss: US$72.6m (down US$80.2m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 23%, compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Tillkännagivande • Aug 10
BioLife Solutions, Inc. Provides Revenue Guidance for the Year 2022 BioLife Solutions, Inc. provided revenue guidance for the year 2022. Total revenue for 2022 is expected to range from $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and organic growth of 37% to 43%. COVID-19 related revenue is expected to account for approximately 8% of total revenue. Tillkännagivande • Aug 03
BioLife Solutions, Inc. to Report Q2, 2022 Results on Aug 09, 2022 BioLife Solutions, Inc. announced that they will report Q2, 2022 results After-Market on Aug 09, 2022 Recent Insider Transactions • Jul 15
President & COO recently sold €144k worth of stock On the 12th of July, Roderick de Greef sold around 9k shares on-market at roughly €15.69 per share. This was the largest sale by an insider in the last 3 months. Roderick has been a seller over the last 12 months, reducing personal holdings by €1.2m. Tillkännagivande • Jun 10
BioLife Solutions, Inc. Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services BioLife Solutions, Inc. announced that its SciSafe(R) biostorage services platform will now offer a fleet of refrigerated and ultra-low temperature ("ULT") truck trailers to manage local cold chain movements for customers' biologic materials. This fleet provides an ideal transportation solution for any biologic product movement requiring ULT storage between -20degC and - 196degC without the added need for dry ice as it moves from pharmaceutical manufacturer to contract development and manufacturing company ("CDMO") sites and can be deployed worldwide. Running on generator power with two cooling systems, the fleet can also carry up to ten plugged in, powered, and running upright ULT freezers at a time, expanding supported temperatures to as low as -86degC with equipment to track location and trailer temperatures, in real time. The controlled temperature trailers can also transport liquid nitrogen storage freezers containing biologic materials stored at -150degC and colder. From day-to-day sample management to deploying clinical trial medicines that need ULT freezers to clinical sites, life sciences organizations, and particularly large pharmaceutical companies, face significant challenges when moving high value assets that have stringent storage temperature requirements. This new domestic transport service enables operational flexibility and reduced risk through the same provider SciSafe customers already trust with their sample management. Tillkännagivande • May 10
Biolife Solutions, Inc. Affirms Revenue Guidance for the Year 2022 BioLife Solutions, Inc. affirming revenue guidance for the year 2022. Total revenue for 2022 is expected to range from $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39%. COVID-19 related revenue is expected to account for approximately 8% to 9% of total revenue. Tillkännagivande • May 03
BioLife Solutions, Inc. to Report Q1, 2022 Results on May 09, 2022 BioLife Solutions, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022 Tillkännagivande • May 02
BioLife Solutions, Inc., Annual General Meeting, Jun 09, 2022 BioLife Solutions, Inc., Annual General Meeting, Jun 09, 2022, at 09:00 Pacific Standard Time. Agenda: To elect the five (5) directors named in the attached proxy statement to serve until his/her successor is duly elected and qualified, unless he/she resigns, is removed or otherwise is disqualified from serving as a director of the Company; to approve on a non-binding, advisory basis the compensation of our named executive officers; To ratify the appointment by our Board of Directors of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; to amend the Second Amended And Restated 2013 Performance Incentive Plan to increase the aggregate number of shares of common stock which may be issued under the plan by 2,000,000 shares from 6,500,000 to 8,500,000 shares; and to consider other matters if any. Tillkännagivande • Mar 04
BioLife Solutions, Inc. announced delayed annual 10-K filing On 03/02/2022, BioLife Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.22 loss per share (down from US$0.09 profit in FY 2020). Revenue: US$119.2m (up 148% from FY 2020). Net loss: US$8.38m (down 442% from profit in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 37%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 01
BioLife Solutions, Inc. Provides Revenue Guidance for 2022 BioLife Solutions, Inc. provided revenue guidance for 2022. Total revenue for 2022 is expected to range from $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39%. COVID-19 related revenue is expected to account for approximately 8% to 9% of total revenue. Tillkännagivande • Feb 22
BioLife Solutions, Inc. to Report Q4, 2021 Results on Feb 28, 2022 BioLife Solutions, Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022 Recent Insider Transactions • Jan 12
President & COO recently sold €293k worth of stock On the 7th of January, Roderick de Greef sold around 11k shares on-market at roughly €27.12 per share. This was the largest sale by an insider in the last 3 months. Roderick has been a seller over the last 12 months, reducing personal holdings by €978k. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS US$0.002 (vs US$0.036 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$33.8m (up 200% from 3Q 2020). Net income: US$79.0k (up US$1.21m from 3Q 2020). Profit margin: 0.2% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year whereas the company’s share price has increased by 68% per year. Recent Insider Transactions • Oct 28
CFO & Secretary recently sold €91k worth of stock On the 25th of October, Roderick de Greef sold around 2k shares on-market at roughly €38.42 per share. In the last 3 months, they made an even bigger sale worth €391k. Roderick has been a seller over the last 12 months, reducing personal holdings by €660k. Recent Insider Transactions • Oct 20
Chairman & CEO recently sold €111k worth of stock On the 14th of October, Michael Rice sold around 3k shares on-market at roughly €34.50 per share. In the last 3 months, there was an even bigger sale from another insider worth €391k. Michael has been a seller over the last 12 months, reducing personal holdings by €406k. Tillkännagivande • Sep 02
BioLife Solutions, Inc. (NasdaqCM:BLFS) completed the acquisition of the remaining unknown majority stake in Sexton Biotechnologies. BioLife Solutions, Inc. (NasdaqCM:BLFS) entered into an agreement to acquire the remaining unknown majority stake in Sexton Biotechnologies for $24.7 million on August 9, 2021. The transaction is for $24 million, in consideration for 506,382 newly issued shares, with an aggregate value equal to $30 million of BioLife common stock. An escrow share deposit shall be made in the escrow account and $0.1 million will be deposited into a fund for payment to the Seller. The escrow property will be held for a period of up to eighteen months after the closing. Taking into consideration liquidation preferences, BioLife will retain 19.9% of the consideration due to Sexton shareholders. Sexton team will be joining BioLife. The obligations of the parties to complete the Closing are subject to various customary conditions including the approval of Sexton’s stockholders. The transaction is expected to close on or before September 1, 2021. The transaction is expected to be moderately accretive to adjusted net income per share (non-GAAP) in 2022 and beyond.
BioLife Solutions, Inc. (NasdaqCM:BLFS) completed the acquisition of the remaining unknown majority stake in Sexton Biotechnologies on September 1, 2021. Recent Insider Transactions • Aug 29
Independent Director recently sold €84k worth of stock On the 25th of August, Joseph Schick sold around 2k shares on-market at roughly €44.72 per share. In the last 3 months, there was an even bigger sale from another insider worth €391k. Insiders have been net sellers, collectively disposing of €45m more than they bought in the last 12 months. Recent Insider Transactions • Aug 20
CFO & Secretary recently sold €391k worth of stock On the 18th of August, Roderick de Greef sold around 10k shares on-market at roughly €38.14 per share. This was the largest sale by an insider in the last 3 months. Roderick has been a seller over the last 12 months, reducing personal holdings by €545k. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.70 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$31.2m (up 215% from 2Q 2020). Net income: US$7.88m (up US$24.3m from 2Q 2020). Profit margin: 25% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Aug 13
BioLife Solutions, Inc. Revises Revenue Guidance for the Full Year of Fiscal Year 2021 BioLife Solutions, Inc. revised revenue guidance for the full year of fiscal year 2021. For the year, the company expects revenue to range from $108 million to $117 million, reflecting year-over-year growth of 125% to 143%. This revised guidance is up from previous guidance of $106 to $115 million, due to the expected $2 million in contributed revenue from Sexton which is expected to close on or about September 1, 2021. Tillkännagivande • Aug 11
BioLife Solutions, Inc. (NasdaqCM:BLFS) entered into an agreement to acquire an unknown majority stake in Sexton Biotechnologies for $24.7 million. BioLife Solutions, Inc. (NasdaqCM:BLFS) entered into an agreement to acquire an unknown majority stake in Sexton Biotechnologies for $24.7 million on August 9, 2021. The transaction is for $24.0 million, in consideration for 506,382 newly issued shares of BioLife common stock. Taking into consideration liquidation preferences, BioLife will retain 19.9% of the consideration due to Sexton shareholders. Sexton team will be joining BioLife. The transaction is expected to close on or before September 1, 2021. The transaction is expected to be moderately accretive to adjusted net income per share (non-GAAP) in 2022 and beyond. Recent Insider Transactions • Jul 27
Chief Revenue Officer recently sold €97k worth of stock On the 20th of July, Marcus Schulz sold around 3k shares on-market at roughly €38.33 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €47m more than they bought in the last 12 months. Recent Insider Transactions • Jul 24
Chief Revenue Officer recently sold €97k worth of stock On the 20th of July, Marcus Schulz sold around 3k shares on-market at roughly €38.33 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €47m more than they bought in the last 12 months. Executive Departure • Jul 15
Independent Non-Executive Chairman Raymond Cohen has left the company On the 12th of July, Raymond Cohen's tenure as Independent Non-Executive Chairman ended after 7.6 years in the role. As of March 2021, Raymond still personally held 22.76k shares (€697k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • May 15
First quarter 2021 earnings released: US$0.034 loss per share (vs US$1.02 profit in 1Q 2020) The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$16.8m (up 39% from 1Q 2020). Net loss: US$1.12m (down 105% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 14
Biolife Solutions, Inc. Updates Earnings Guidance for the Full Year 2021 BioLife Solutions, Inc. updated earnings guidance for the full year 2021. For the period, the company's Total revenue for 2021 is now expected to range from $106 million to $115 million, reflecting year-over-year growth of 120% to 129%. This revised guidance is up from original estimates of $101 to $105 million. 
